Chrysantis Announces New Patent for Carotenoids from Marigolds

In August 2009, Chrysantis announced the formation of the Zeaxanthin Trade Association. Its primary goal is to increase global awareness and promote the use of dietary zeaxanthin.

23 Sep 2009 --- Chrysantis, Inc. has been granted United States patent 7,575,766 for Tagetes erecta (Marigold) With Altered Carotenoid Compositions and Ratios. This patent is a continuation of Chrysantis’ US patents 6,784,351 and 7,033,622 which cover not only zeaxanthin produced by marigolds, but also beta carotene, phytoene, phytofluene, cryptoxanthins and other carotenoids synthesized in the petals and leaves of Chrysantis marigolds.  

Chrysantis now has a marigold collection that offers a unique, sustainable and efficient means of producing carotenoids for human nutrition.  

“We are truly excited about the approval of this last patent for our marigolds,” says Manuel Pavon, General Manager for Chrysantis. “We have worked hard through natural selection and breeding to bring healthy, natural carotenoids to the nutritional market place that enhance human health safely and effectively."

EZEyes zeaxanthin, made from marigolds, is the same form of zeaxanthin found naturally in fruits and vegetables. In August 2009, Chrysantis announced the formation of the Zeaxanthin Trade Association. Its primary goal is to increase global awareness and promote the use of dietary zeaxanthin.

Zeaxanthin, in combination with lutein, is a critical nutrient for eye health that can help guard against vision problems such as Age-Related Macular Degeneration (AMD) and cataracts. New research has also shown a link between zeaxanthin and cognitive function.